- Home
- OPBK vs PRQR Comparison
OPBK vs PRQR Comparison
Compare OPBK & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPBK
- PRQR
- Stock Information
- Founded
- OPBK 2005
- PRQR 2012
- Country
- OPBK United States
- PRQR Netherlands
- Employees
- OPBK N/A
- PRQR N/A
- Industry
- OPBK Major Banks
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- OPBK Finance
- PRQR Health Care
- Exchange
- OPBK Nasdaq
- PRQR Nasdaq
- Market Cap
- OPBK 204.6M
- PRQR 232.8M
- IPO Year
- OPBK 2018
- PRQR 2014
- Fundamental
- Price
- OPBK $14.54
- PRQR $2.25
- Analyst Decision
- OPBK Hold
- PRQR Strong Buy
- Analyst Count
- OPBK 1
- PRQR 8
- Target Price
- OPBK $15.50
- PRQR $8.88
- AVG Volume (30 Days)
- OPBK 44.3K
- PRQR 319.5K
- Earning Date
- OPBK 10-23-2025
- PRQR 08-07-2025
- Dividend Yield
- OPBK 3.40%
- PRQR N/A
- EPS Growth
- OPBK 8.15
- PRQR N/A
- EPS
- OPBK 1.48
- PRQR N/A
- Revenue
- OPBK $84,078,000.00
- PRQR $20,129,184.00
- Revenue This Year
- OPBK $22.05
- PRQR N/A
- Revenue Next Year
- OPBK $10.50
- PRQR N/A
- P/E Ratio
- OPBK $9.54
- PRQR N/A
- Revenue Growth
- OPBK 9.17
- PRQR 8.65
- 52 Week Low
- OPBK $10.43
- PRQR $1.07
- 52 Week High
- OPBK $18.57
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- OPBK 65.13
- PRQR 57.03
- Support Level
- OPBK $14.10
- PRQR $2.18
- Resistance Level
- OPBK $14.37
- PRQR $2.33
- Average True Range (ATR)
- OPBK 0.37
- PRQR 0.13
- MACD
- OPBK 0.08
- PRQR 0.02
- Stochastic Oscillator
- OPBK 82.23
- PRQR 84.91
About OPBK OP Bancorp
OP Bancorp is engaged in the general commercial banking business in Los Angeles, Orange, and Santa Clara Counties, California, Carrollton, Texas, and Las Vegas, Nevada. The Bank is focused on serving the banking needs of small- and medium-sized businesses, professionals, and residents with a particular emphasis on Korean and other ethnic minority communities. It operates with eleven full branches.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.